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The effect of diphosphonate on calcium phosphate crystallization
in urine in vitro. Disodium ethane-l-hydroxy-l, 1-diphosphonate
(EHDP) was added to human urine in vitro and tested for its
effect on nucleation, crystal growth and crystal dissolution of
brushite (CaHPO4 . 2H20), the probable nidus for certain
calcium-containing renal stones. The EHDP (0.5 to 8 mg of
P/liter) increased the formation product of brushite, indicating
an inhibition of nucleation of brushite. It inhibited the crystal
growth of brushite in every urine specimen tested. Finally, it
facilitated the crystal dissolution of brushite in some urine
specimens. Thus, EHDP might be clinically useful in the pre-
vention of renal stone formation.
Effet du diphosphonate sur Ia cristallisation du phosphate de
calcium dans l'urine in vitro. Du disodium éthane-l-hydroxy-l,
1-diphosphonate (EHDP) a eté ajouté in vitro a de l'urine hu-
maine et l'on a étudié ses effets sur Ia nucleation, Ia croissance
cristalline et Ia dissolution cristalline de la brushite (CaHPO4 -
2H20), Ic germe probable de certains calculs urinaires contenant
du calcium. L'EHDP (0,5—0,8 mg P/litre) augmente le produit
de formation de Ia brushite, ce qui indique une inhibition de sa
nucleation. Ii inhibe Ia croissance cristalline de Ia brushite dans
toutes les urines CtudiCes. Enfin, ii facilité Ia dissolution cristal-
line de Ia brushite dans quelques échantillons d'urine. Ainsi,
l'EHDP peut peut-être avoir une utilitC clinique dans Ia prC-
vention des calculs urinaires.
The importance of brushite (CaHPO4 .2H20) as the
possible nidus in the formation of certain renal stones
has been previously emphasized [1—3]. Brushite was
the solid phase formed from urine under the influence
of an organic matrix or by spontaneous precipitation.
This scheme for stone formation was supported by the
observation of Chambers, Hodgkinson and Hornung,
who found the "nidus" of the majority of small stones
to be composed of calcium phosphate by electron
probe analysis [4].
Thus, an effective means for the control of renal
stone formation may be one which inhibits or retards
the development of the brushite nidus. Several diphos-
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phonates have been reported to affect the crystal-
lization of calcium phosphates (hydroxyapatite) in
vitro in an artificial solution at pH 7.4 [5—7]. The pur-
pose of this report is to analyze the effect of one of
these diphosphonates, disodium ethane- 1-hydroxy- 1,
1-diphosphonate (EHDP), on the crystallization of
brushite in human urine. It will be shown that EHDP,
added to urine in vitro, markedly inhibits the nuclea-
tion and crystal growth of brushite.
Methods
One 24-hour urine specimen was collected from
each subject without stones (control group) and from
each patient with calcareous renal stones (nephro-
lithiasis group) according to the procedure previously
described [8]. EHDP was slowly introduced into urine
under constant stirring from a stock aqueous solution
(0.4 mg of P/ml) until the desired concentration in
urine was attained (0.5 to 8 mg of P/liter or 2.02 to
32.2 mg of EHDP/liter). Studies of nucleation,
crystal growth or crystal dissolution of brushite were
performed in each urine specimen with and without
addition of EHDP. These studies were conducted at
37°C at constant pH. The pH was kept within 0.1 of
the desired pH by frequent titration with 0.1N HCI of
0.1N NaOH.
Effect on EHDP on the nucleation of brushite. The
effect of EHDP on the nucleation of brushite was
examined from the changes in the formation product
of brushite. As shown previously [3, 9], the formation
product represents the lowest state of supersaturation
at which nucleation is initiated. Thus, an increase in
the formation product indicates an inhibition of
nucleation. Conversely, a decrease in the formation
product represents facilitation of nucleation.
The formation product was calculated according to
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the method described previously [9]. Briefly, the urine
specimens were allowed to become increasingly super-
saturated with respect to brushite by addition of
CaC12. The point of nucleation (formation product)
was indicated by the appearance of a visible precipitate,
or by a sudden decline in the activity product of Ca +
and HPO, which was calculated according to the
procedure described previously [1]. The formation
product was measured 24 hours after the addition of
CaCI2. It was expressed as the activity product, rather
than as the ratio with the solubility product.
The formation product was determined for six
urine specimens from the nephrolithiasis group
(idiopathic hypercalciuria) and three from the control
group, with and without EHDP (0.5 to 8 mg of P/liter)
at PH 6.4.
The formation product of brushite, measured at 24
hours, represents a steady-state value [3]. The forma-
tion product decreased with time until a steady-state
value was reached at about 6 to 24 hours. This decline
in formation product of brushite probably reflected
the fact that, at a lower value of formation product,
the "activation energy" for spontaneous nucleation
was less, requiring a longer period for nucleation. It is
unlikely that a heterogeneous nucleation occurred
during the 24 hours of incubation, for example, on
"active sites on the walls of the vessel" as suggested by
Robertson for octacalcium phosphate [10]. Increasing
the surface area of glass exposed to incubate or sili-
conizing the vessel did not alter the formation product
of brushite. Analysis revealed that the precipate
formed was brushite [3]. The formation product of
brushite (at 24 to 48 hours) was independent of pH
below pH 6.9 [3]. Finally, in contrast to the finding of
Robertson for octacalcium phosphate at a higher pH
range than in this study [10], EHDP increased the
formation product of brushite at 24 hours as well as at
earlier time periods (Greebon D, Ohata M, and Pak
CYC: unpublished observations).
Effect of EHDP on the crystal growth of brushite. The
urine specimens were rendered metastably super-
saturated with respect to brushite by the addition of
CaCI2. A solution of CaCl2 (5 mg of calcium/mi) was
slowly added to each sample under stirring until the
activity product of Ca + and HPO' of urine was just
below the formation product for brushite. The growth
of a known amount of brushite from these metastably
supersaturated specimens was determined from the
decline in the activity product of Ca + and HPO
after the addition of brushite (CaHPO4.2H20,
Mallinkrodt). This decline is the result of the uptake
of Ca + and HPO' by brushite, and, therefore,
indicated crystal growth of brushite.
The crystal growth was quantitated as follows. The
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Fig. 1. Quantitation of crystal growth inhibition. The horizontal
dashed line indicates the theoretical activity product of brushite
(K8). After incubation with brushite (10mg/mi), the final
activity product (c) is equivalent to K,, indicating complete
crystal growth. After incubation with a smaller amount of
brushite (0.5 mg/ml), the final activity product (b) is much
higher, indicating inhibition of crystal growth.
urine specimen was incubated separately at two con-
centrations of brushite (0.5 and 10 mg/mi). In the
presence of a large amount of brushite, the effect of
inhibitors of crystal growth are overcome and the
steady state with respect to brushite is soon reached, as
indicated in a schematic diagram in Fig. 1. In this
figure, the solubility of brushite (K80) is shown by the
broken line. After incubation with brushite (10 mg/mi),
the activity product of the ambient fluid decreases
until it reaches the solubility of brushite at (c) or K50.
This situation represents the complete crystal growth.
At the lower concentration of brushite, the activity
product may not reach the solubility of brushite
because of the presence of inhibitors of crystal growth.
The final activity product (b) is lower than the initial
activity product (a), but much higher than K30 or (c).
The extent of crystal growth of brushite (at a con-
centration of 0.5 mg/ml) may be expressed as a—b/a—c
x 100%. Conversely, the extent of inhibition of
crystal growth may be expressed as (1—a—b/a—c) 100
or b—c/a—c x 100%.
This study evaluated the growth of brushite at a
concentration of 0.5 mg/mi of urine at two days of
incubation at pH 6.4. The crystal growth of brushite
was examined in four urine samples from patients
with nephrolithiasis (three with idiopathic hyper-
calciuria and one with primary hyperparathyroidism),
and in five samples from control subjects. Each sample
was tested with and without EHDP (2 mg of P/liter).
Effect of EHDP on crystal dissolution. Specimens
which were undersaturated by dilution with distilled
water were chosen for study. These specimens were
incubated with brushite at a concentration of 2 mg/mI
of urine for two days at constant pH of 6.4. Dissolution
of added brushite was indicated by the increase in the
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activity product of Ca + and HPO in the super-
natant urine. The crystal dissolution was examined in
four urine samples from patients with nephrolithiasis
(idiopathic hypercalciuria) and in four samples from
control subjects. Each sample was tested with and
without EHDP (2 mg of P/liter).
Results
Effect of EHDP on the formation product of brushite.
The EHDP increased the formation product of brush-
ite in every urine specimen tested (Fig. 2). This effect
was usually more pronounced at higher concentrations
of EHDP. Thus, EHDP inhibited the nucleation of
brushite.
Effect of EHDP on the crystal gro wth of brushire. The
effect of varying amounts of EHDP on the crystal
growth of brushite (0.5 mg/ml) was examined in
0.5 mg of P EHDP/liter
0 mg of P EHDP/Iiter
0 • ______________0 1 2 3 4 5
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Fig. 3. Effect of EHDF on crystal growth of brushite. To the same
supersaturated urine specimen, containing different amounts of
EHDP, brushite (0.5 mg/mI) was added, and the activity pro-
duct of Ca + and HPO in supernatant urine was measured
for five days. The activity product declined to a smaller degree or
did not decrease in the presence of EHDP, indicating inhibition
of crystal growth.
detail (Fig. 3). In the absence of EHDP, the urinary
activity product of Ca + and HPO declined
rapidly towards the state of solubility for brushite
from the metastably supersaturated state. This decline
(or crystal growth) was inhibited by EHDP. The in-
hibition of crystal growth of brushite was more pro-
nounced at higher concentrations of EHDP. At the
higher concentrations of EHDP utilized in this study
(2 and 8 mg of P/liter), the activity product of Ca + +
and HPO did not significantly decline during in-
cubation with brushite, indicating a complete inhibi-
tion of crystal growth of this amount of brushite.
The crystal growth of varying amounts of brushite
(0.5 to 10 mg/ml) at a fixed concentration of EHDP
(2 mg of P/liter) was examined (Fig. 4). At high con-
centration of brushite (10 mg/ml), the curve describing
the decline in the activity product of Ca + and
HPO; approximated that for the solubility of brush-
ite in the absence of EHDP (K5). Thus, the effect of
EHDP (2 mg of P/liter) was overcome by a large
amount of brushite (10 mg/ml). This situation repre-
sents the complete crystal growth. At lower concen-
trations of brushite, the activity product of Ca + + and
HPO4 did not reach the solubility of brushite (K5),
indicating inhibition of crystal growth of brushite by
EHDP. These considerations justified the method for
calculation of inhibition of crystal growth of brushite,
which was described in the Methods section.
The inhibition of crystal growth of brushite (0.5
mg/ml) was calculated for specimens, with and without
added EHDP (2 mg of P/liter) (Fig. 5). In all speci-
mens, EHDP enhanced the inhibition of crystal
growth of brushite.
Effect of EHDF on the crystal dissolution of brushite.
In Table 1, the final activity products of Ca + + and
HPO for eight undersaturated urine specimens
after incubation with brushite in the presence and
an,, aHpo
x 10'
1.5
1.0
________ 2 mg of P and
8 mg of P EHDP/litcr
404 Ohata and Pak
Activity product of brushite
Initial Final
Without With
EHDP EHDP
Nephrolithiasis 1
2
3
4
2.2 x l0
2.0 x l0-
1.2 x107
0.62x107
4.7x l0- 6.1 x l0-
3.9 x l0- 6.1 x 1O
2.7x107 3.1x107
2.8x107 2.7x107
Control 5
6
7
8
2.3 x l0
0.24x107
0.55x107
3.0 x107
3.4x l0 3.4x l0
2.6xlO-7 2.3xl07
l.4x107 2.2x10-7
4.5x107 4.5x10
a Undersaturated urine specimens, with and without added
EHDP did not affect crystal dissolution. However, in
three specimens (1, 2 and 7), the final activity product
was higher in the presence of EHDP; thus EHDP en-
hanced the dissolution of brushite.
Discussion
Diphosphonates are a group of synthetic com-
pounds which, like their natural analogues pyrophos-
phates, inhibit the nucleation, growth and dissolution
of calcium phosphates [5—7]. Since they are not
metabolized in vivo, and are excreted unaltered in
urine after oral absorption [11], they may be clinically
useful in the prevention of the formation of renal stones
of calcium phosphate origin. This hypothesis was
tested by examining the effect of one of the diphos-
phonates (EHDP) on the crystallization of brushite
(CaHPO4.2H20), the nidus for certain calcium-
containing renal stones (1—3, 8, 9].
The effects of EHDP, added to urine in vitro, were
threefold. First, it increased the formation product of
brushite. Since the formation product measures the
lowest state of supersaturation at which nucleation is
initiated [3, 9], the results indicate an inhibition of
nucleation of brushite by EHDP. The extent of this
inhibition varied among urine specimens, as the incre-
ment in the formation product which was caused by
the same amount of EHDP ranged widely (Fig. 2).
The exact mechanism for this variation is not known.
Secondly, EHDP invariably inhibited the crystal
Table 1. Effect of EHDP on the crystal dissolution of
brushite
EHDP (2 mg of P/liter), were incubated with brushite (2 mg/mI).
The final activity product of Ca + and HPO4 of ambient fluid
was higher than the initial activity product in each specimen,
indicating partial dissolution of brushite. In three specimens
(1, 2 and 7), the final activity product was greater in the presence
of EHDP, indicating that EHDP had stimulated the dissolution
of brushite. This difference was significant since it exceeded the
precision of measurement for activity product of 5%.
xIO'
:i:
l::
— 6 mg1nil
I 0 10 mg ml
0 0 1 2
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Fig. 4. Dependence of EHDP-induced inhibition of crystal growth
on the concentration of brushite. Different amounts of brushite
were incubated with the same supersaturated urine specimen
containing EHDP (2 mg of P/liter), and the activity product of
urine supernatant was measured for two days. The final activity
product of urine in the absence of EHDP (K) (not shown here)
was equal to the final activity product after incubation with
brushite (10 mg/mI) in the presence of EHDP. The results indi-
cate that this amount of brushite (10 mg/mI) overcomes the
effect of EHDP. However, in the presence of smaller amounts of
brushite, the final activity products were higher than L.
indicating that EHDP was inhibiting crystal growth of these
amounts of brushite.
absence of EHDP are shown. In all specimens, the
final activity product was higher than the original
value, indicating dissolution of brushite. In five urine
specimens, EHDP (2 mg of P/liter) did not signifi-
cantly alter the final activity product, suggesting that
Inhibition of
crystal growth, %
100
80
60
40
20
0
Fig. 5. Effect of EHDP (2mg ofP/liter) on the crystal growth of
brushite (0.5 mg/mI). In the absence of EHDP, some specimens
showed an inhibition of crystal growth, probably indicating the
presence of other inhibitors of nucleation. In the presence of
EHDP, every specimen showed an enhancement of inhibition of
crystal growth of brushite. Asterisks denote specimens from
nephrolithiasis group.
0 2
EHDP concentration, mg of P/liter
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growth of brushite. Finally, it stimulated the dissolu-
tion of brushite in certain urine specimens, in contrast
to the observation by Fleisch, Russell and Francis
using artificial solution [12]. A definitive conclusion
cannot be drawn without further study. However, if
the stimulation of dissolution of brushite is caused by
EHDP, it is probably not the result of "peptisation"
[13]. In the presence of 0.6 moles/liter of diphos-
phonate, Robertson et a! [13] showed that hydroxy-
apatitie formed a nonsedimentable colloidal suspensa-
tion. Thus, the concentrations of calcium and
phosphate in the supernatant fluid were higher in the
presence of EHDP. However, in the range of con-
centration utilized in this study (0.5 to 8 mg of P/liter
or 0.08 to 0.129 moles/1iter), EHDP does not cause
peptisation of brushite (Greebon D, Ohata M, and
Pak CYC: unpublished observations).
Thus, the combined effects of EHDP were the pre-
vention of the establishment of the brushite nidus and,
possibly, under certain situations the dissolution of
brushite even when it is established. These effects were
produced by EHDP ranging from 0.5 to 8 mg of
P/liter. Recent studies suggest that this concentration
range in urine could be achieved by a dose of EHDP
equal to or somewhat less than 20 mg/kg/day orally,
which is the dose customarily used for the treatment of
metabolic bone disease. Michael, King and Wakim
[11] have shown in experimental animals that 1 to
20% of the orally administered EHDP is absorbed;
approximately 50% of the absorbed EHDP is excreted
in urine. For a 70-kg man excreting 2 liters of urine/
day and receiving 20 mg of EHDP/kg/day, urinary
concentration of EHDP would be expected to be
0.87 mg of P/liter for 1% absorption and 17.4 mg of
P/liter for 20% absorption. In an in vivo study now in
progress (Ohata M and Pak CYC: unpublished
observations), the urinary excretion of EHDP ranged
from 7 to 10 mg of P/day after a short-term treatment
of patients with nephrolithiasis at a dosage of 20 mg of
EHDP/kg/day.
Findings of these in vitro studies indicate that EHDP
might be clinically useful in the treatment of renal
stones originating from the nidus of brushite, such as
many stones of calcium phosphate [1—3] and certain
stones of calcium oxalate [14, 4]. Further, EHDP may
inhibit the formation of calcium oxalate stones
occurring independently of brushite nidus, since it has
been shown to increase the formation product [15],
and inhibit the crystal growth (Pak CYC: unpublished
observations) and aggregation [16] of calcium oxalate.
These conclusions are supported by the studies of
Fraser et al [15], showing that EHDP inhibits the
formation of bladder stones of both calcium phosphate
and calcium oxalate in the rat. However, there is some
evidence that diphosphonates produce osteomalacia in
man [17]. This potential side-effect should be carefully
considered if a long-term treatment of nephrolithiasis
with EHDP is contemplated.
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